Skip to main content
OpenTrials
Completed

NCT Number: NCT04177316

Hypermethylation of VTRNA2-1 Promoter in HCC Outcome

The clinic-pathological data were retrieved from the cancer registry database from the Cancer Center of Chang Gung Memorial Hospital, Linkou branch. Of the 92 HCC patients with partial hepatectomies enrolled. The biological specimen was studied with approval.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hepatocellular Carcinoma Resectable Disease Attributes Pathologic Processes Pathological Conditions, Signs and Symptoms Recurrence

Age range

20 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Ming-Chin Yu

Taoyuan, 333, Taiwan

About this study

This study was approved by the Institute Review Board (IRB) of Chang Gung Memorial Hospital, Linkou Branch (IRB 201801969B0). The clinic-pathological data were retrieved from the cancer registry database from the Cancer Center of Chang Gung Memorial Hospital, Linkou branch. Of the 92 HCC patients with partial hepatectomies enrolled, all patients had curative hepatectomy and those with different cancers were excluded. HCC tumor tissue and normal tissue, 3 cm from the tumor margin, were stored immediately in a -80 degree freezer at the Central Biobank of Chang Gung Memorial Hospital. The personal information was protected with decoding and registered with number.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

subjects with pathologic diagnosis of hepatocellular carcinoma curative partial hepatectomies

Exclusion criteria

history of different malignant disease. subjects cannot be treated with curative surgery.

Treatment and study plan

Primary outcomes

  1. disease free survival (DFS)

    Time frame: a month

    The length of time from curative hepatectomies treatment and recurrence or mortality

Secondary outcomes

  1. Overall survival

    Time frame: a month

    The length of time from hepatectomies treatment for HCC and still alive.

Sponsors and collaborators

Lead sponsor

Chang Gung Memorial Hospital

Other

Registry information

Official study title

Differential Hypermethylation Status of the VTRNA2-1 Promoter in Hepatocellular Carcinoma as an Independent Factor After Partial Hepatectomy

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Nov 26, 2019
Registry last updated
Nov 26, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.